| 规格: | 98% |
| 分子量: | 340.4 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
Background:
WYC-210, a Tazarotene derivative, is a retinoid compound with lower anticancer activity[1].
WYC-210 (10 μM; 5 days) inhibits cell growth of B16-F1 TRC cells with an inhibition rate of 18.1%[1].
[1]. Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1.
